{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011149","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.970741+00:00","generated_at":"2026-05-17T14:45:47.076450+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aprea Therapeutics Q2 net loss $0.53/sh; cash $16.5M; clinical activity in APR-1051 and ATRN-119","bullets":["Cash and cash equivalents $16.5M as of June 30, 2025, down from $22.8M at Dec 31, 2024; runway into Q2 2026.","Q2 2025 operating loss $3.4M vs $3.8M in Q2 2024; net loss $3.2M ($0.53 per share) vs $3.5M ($0.58 per share).","Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051: 3 patients with stable disease at 70mg/100mg; dose escalation to 150mg planned.","Phase 1/2a ABOYA-119 trial of ATRN-119: 7 patients stable disease, 3 with tumor shrinkage (7%-21%) at 550mg BID; now dosing 400mg BID.","Additional safety/efficacy data expected H2 2025; RP2D for ATRN-119 and dose-escalation completion for APR-1051 expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011149","json":"https://secwatch.observer/filing/0001558370-25-011149.json","markdown":"https://secwatch.observer/filing/0001558370-25-011149.md","text":"https://secwatch.observer/filing/0001558370-25-011149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025011149/0001558370-25-011149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025011149/apre-20250812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:45:47.076450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}